Fiche société
Tianjin Huanhu Hospital
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications2liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| UCAR T-cellThis is an open label, single-site, dose-escalation study in up to 12 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells. | Myasthénie | Phase 1 | China | À vérifier | |
| UCAR T-cellThis is an open label, single-site, dose-escalation study in up to 12 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells. | Myasthénie | Phase 1 | Immunomodulation + Thérapie cellulaire | China | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| UCAR T-cell | Myasthénie | Phase 1 | NCT06939166 | Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases | RECRUITING |
Publications
2| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| UCAR T-cell | Recent advances in universal chimeric antigen receptor T cell therapy. | Journal of hematology & oncology | ||
| UCAR T-cell | Universal CAR-T Cell Therapy for Cancer Treatment: Advances and Challenges. | Oncology research |